Development of a New Class of Broad-Stage Antimalarial Agents

新型多阶段抗疟药物的开发

• 批准号: nhmrc : 2000087
• 金额: $ 72.9万
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-new-class-antimalarial-agents/1779504
• 关键词: Development; New; Class; Broad; Stage

In 2017, there were almost 220 million cases of malaria across 90 different countries, associated with 435,000 deaths, and with 65-70% of all malaria deaths tragically being children under the age of 5 years old. No significant progress in reducing global malaria cases has been made over the last 4 years and the need for new and better treatments remains dire. In this research and development plan, we will develop novel and safer drugs for the treatment of drug resistant malaria.

2017年，90个不同国家有近2.2亿疟疾病例，导致43.5万人死亡，可悲的是，所有疟疾死亡人数中有65%-70%是5岁以下儿童。在过去4年中，在减少全球疟疾病例方面没有取得重大进展，迫切需要新的更好的治疗方法。在这项研发计划中，我们将开发治疗耐药疟疾的新的、更安全的药物。